AI Article Synopsis

  • - This study aimed to identify the best type of central venous catheter (CVC) for pediatric patients with Hodgkin lymphoma by examining complications associated with different types during a retrospective analysis from 2015 to 2021.
  • - Out of 98 patients, common complications included local infections/irritations, malfunctions, and central venous thrombosis (CVT), with single lumen peripherally inserted central catheters (PICCs) showing a significantly higher risk of complications compared to totally implantable venous access ports (TIVAPs).
  • - The study recommends using TIVAPs over PICCs for pediatric HL patients, particularly if they have risk factors for CVT, and suggests further research on the use

Article Abstract

Purpose: The purpose of this study was to determine the most optimal central venous catheter (CVC) for pediatric patients with Hodgkin lymphoma (HL) in terms of complications.

Methods: A retrospective study including patients diagnosed with HL from 2015 to 2021 at the Princess Máxima Center was performed. Patients were followed from CVC insertion until removal or 06-2021, whichever came first. The primary outcome was the CVC-related complication incidence rate (IR) per 1000 CVC-days. Furthermore, the incidence rate ratio (IRR) was calculated by comparing complication IRs between peripherally inserted central catheters (PICC) and totally implantable venous access ports (TIVAP). Additionally, risk factors for central venous thrombosis (CVT) were identified.

Results: A total of 98 patients were included. The most frequently observed complications were local irritation/infections (18%; IR 0.93), malfunctions (15%; IR 0.88), and CVC-related CVTs (10%; IR 0.52). Single lumen PICCs were associated with a higher risk of complications (49% vs. 26%; IRR 5.12, CI95% 2.76-9.50), severe complications (19% vs. 7%; IRR 11.96, CI95% 2.68-53.42), and early removal (18% vs. 7%; IRR 9.96, CI95% 2.18-45.47). A single lumen PICC was identified as a risk factor for CVC-related CVT when compared to TIVAPs (12% vs. 7%, IRR 6.98, CI95% 1.45-33.57).

Conclusion: The insertion of a TIVAP rather than a PICC should be recommended for pediatric patients with HL, especially in the presence of CVT-related risk factors. Future trials should evaluate the efficacy and safety of direct oral anticoagulants for the primary prevention of CVT in pediatric patients with a PICC and other CVT-related risk factors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512752PMC
http://dx.doi.org/10.1007/s00520-022-07256-3DOI Listing

Publication Analysis

Top Keywords

pediatric patients
16
central venous
12
risk factors
12
patients diagnosed
8
hodgkin lymphoma
8
incidence rate
8
single lumen
8
cvt-related risk
8
patients
7
irr
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!